Genitourinary Cancers

Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy

Panel members share insights into strategies and barriers to maintenance therapy for patients with bladder cancer.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Thomas Powles, MBBS, MRCP, MD, comments on patient-reported outcome data and quality of life data in patients receiving maintenance therapy for metastatic urothelial cancer.

Brian I. Rini, MD;Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Rana R. Mckay, MD;Tom Powles, MBBS, MRCP, MD

The Exciting Future of Advanced Renal Cell Carcinoma Management

Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.

Marie Carlo, MD;Mehmet Asim Bilen, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. Mckay, MD;Tom Powles, MBBS, MRCP, MD

Unmet Needs in Advanced Renal Cell Carcinoma Management

A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. Mckay, MD;Tom Powles, MBBS, MRCP, MD

Safety and Efficacy Data: The CheckMate 9ER Trial

Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP

Safety and Efficacy Data: The KEYNOTE-426 Trial

Robert Alter, MD, reviews the CheckMate 9ER trial of cabozantinib/nivolumab versus sunitinib in advanced renal cell cancer.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP

Daniel P. Petrylak, MD, Talks About Importance of Mentorships in Genitourinary Oncology

Arnab Basu, MD, MPH, FACP discusses data from the KEYNOTE-426 trial of axitinib/pembrolizumab versus sunitinib in metastatic RCC.

Daniel P. Petrylak, MD

JAVELIN Bladder 101: Study Design and Patient Outcomes

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, reflects upon mentorship during his training to become an oncologist.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

The Role of Biomarkers in Immunotherapy Selection for mUC

Thomas Powles, MBBS, MRCP, MD, discusses recent data from the JAVELIN Bladder 100 trial on maintenance avelumab therapy plus best supportive care versus BSC alone.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Unmet Needs in the Front-Line Setting for Renal Cell Carcinoma

Experts discuss the role of biomarkers in treatment selection for patients with metastatic UC.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. Mckay, MD;Tom Powles, MBBS, MRCP, MD

Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma

A look at the current unmet needs in front-line renal cell carcinoma treatment.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. Mckay, MD;Tom Powles, MBBS, MRCP, MD

Safety and Efficacy Data: The JAVELIN Renal 101 Trial

Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP;Mehmet Asim Bilen, MD;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

April 20th 2022

Chung-Han Lee, MD, PhD, discusses data from the JAVELIN Renal 101 trial of axitinib/avelumab versus sunitinib in metastatic RCC.

Safety and Efficacy Data: The CheckMate 214 Trial

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP;Mehmet Asim Bilen, MD;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

April 20th 2022

Mehmet Asim Bilen, MD, summarizes data from the CheckMate 214 trial on the safety and efficacy of ipilimumab/nivolumab versus sunitinib.

Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. Mckay, MD;Thomas Powles, MD, PhD

Dosing Lenvatinib for First-Line Renal Cell Carcinoma Treatment

Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. Mckay, MD;Thomas Powles, MBBS, MD, MRCP

Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib

An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. Mckay, MD;Tom Powles, MBBS, MRCP, MD

Risk Factors in the Management of Advanced Renal Cell Carcinoma

Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. Mckay, MD;Tom Powles, MBBS, MRCP, MD